Introducing ROADSAVER: A Breakthrough in Carotid Stenting
Announcing the ROADSAVER Carotid Stent System
Terumo Interventional Systems (TIS) is thrilled to announce the early commercial availability of the ROADSAVER™ Carotid Stent System. This FDA-approved device is specifically designed for patients with carotid artery stenosis, aiming to reduce complications that may arise after carotid endarterectomy. With the integration of the Nanoparasol® Embolic Protection System, the ROADSAVER represents a significant advancement in carotid artery stenting procedures.
Innovative Features of the ROADSAVER Stent System
The ROADSAVER Stent System features a unique dual-layer micromesh technology. This design combines the durability of a closed-cell structure with the flexibility characteristic of open-cell stents, effectively addressing complex anatomical challenges during procedures. This innovation marks the first of its kind approved in the United States, focused on maintaining plaque wall adherence and preventing distal embolization, thereby improving patient safety.
Size Options and Design Benefits
Available in a range of widths from 5 to 10 mm and lengths between 22 to 47 mm, the ROADSAVER Stent System is engineered for seamless integration into clinical settings. With a rapid-exchange shaft measuring 143 cm, it offers ease of handling, allowing for re-sheathing and repositioning even after partial deployment. Its low-profile 5Fr design enhances its maneuverability, making it easier for healthcare professionals to utilize.
Expert Endorsements
Chris Pearson, Executive Vice President of US Commercial Operations at Terumo Interventional Systems, emphasizes the stent's commitment to improving patient outcomes. He stated, "ROADSAVER Stent System elevates the reliability of carotid artery stenting by ensuring rapid delivery and precise placement, ideals that our medical community continues to demand." Dr. Michael J. Martinelli, Chief Medical Officer at Terumo Medical Corporation, highlights the stent's cutting-edge technology. "The inner micromesh layer is engineered with exceptionally small pores, providing unprecedented embolic protection. Clinical trials showcasing ROADSAVER's efficacy for symptomatic patients underline its safety and effectiveness, yielding a low complication rate."
Market Release Plans
Limited market release of the ROADSAVER Carotid Stent System is anticipated in the summer months, with a broader launch expected in the fall. This timeline reflects TIS's commitment to ensuring healthcare providers are prepared to deliver this innovative solution to their patients quickly and effectively.
About Terumo Interventional Systems
As a division of Terumo Corporation, Terumo Interventional Systems stands at the forefront of minimally invasive medical technology. They specialize in providing advanced solutions for entry site management, lesion access, and therapeutic interventions. TIS is dedicated to research and development, ensuring their product portfolio plays a critical role in successful coronary and peripheral treatments and a variety of endovascular needs.
About Terumo Corporation
Terumo Corporation, recognized globally and founded over a century ago, strives to enhance healthcare through innovation. The company, headquartered in Tokyo, employs over 30,000 individuals in more than 160 countries, evolving from its origins in thermometer manufacturing to become a leader in medical technologies, including vascular interventions, transfusion systems, and diabetes care solutions.
Frequently Asked Questions
What is the ROADSAVER Carotid Stent System?
The ROADSAVER Stent System is an advanced medical device designed for treating carotid artery stenosis, integrating a dual-layer micromesh for enhanced flexibility and safety.
What makes ROADSAVER unique compared to other stents?
Its dual-layer micromesh design and improved embolic protection features set it apart from traditional carotid artery stents, promising better patient outcomes.
Who is the ROADSAVER intended for?
This stent is targeted at patients with carotid artery stenosis who are at elevated risk of complications following carotid endarterectomy procedures.
When will the ROADSAVER be available for use?
Limited availability is expected by summer 2025, followed by a full launch in the fall.
How can healthcare professionals access the ROADSAVER?
Healthcare providers should stay informed through Terumo Interventional Systems for updates on the availability and training for using the ROADSAVER Stent System.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to [email protected].
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.